New exploratory research suggests that fat-blocking microbeads made from green tea, vitamin E, and seaweed might provide a fresh approach to weight loss, potentially serving as an alternative to common GLP-1 medications and bariatric procedures.
While human trials are still required, researchers in China observed that rats on high-fat diets lost approximately 17% of their body weight after consuming these edible microbeads.
Additionally, these rats showed a decrease in fat tissue, liver damage, and blood fat levels compared to those that did not receive the microbeads.
One researcher from Sichuan University commented that this work could lead to new dietary methods to tackle obesity, a condition impacting around 890 million adults globally. They noted that obesity is the fourth leading cause of death.
Excessive dietary fat is a significant factor contributing to obesity-related conditions like type 2 diabetes, cardiovascular issues, strokes, and certain cancers. The researchers highlighted that reducing dietary fat intake seems promising.
“Losing weight can help individuals prevent long-term health problems like diabetes and heart disease,” stated Yue Wu, one of the study’s authors, in a release from the American Chemical Society (ACS). “Our microbeads act directly in the intestines, blocking the absorption of fat in a gentle, non-invasive way.”
Wu mentioned that the team aimed to create something that aligns more naturally with typical eating patterns and lifestyles.
The microbeads consist of green tea polyphenols, which are antioxidants from tea leaves, combined with vitamin E to bind to fat droplets in the intestine, thus hindering absorption. A coating derived from seaweed shields the beads from stomach acid.
According to ACS, the nearly tasteless beads can be incorporated into everyday foods, including dessert bowls and bubble tea.
During a 30-day trial, rats consuming a diet containing 60% fat, which is notably higher than the usual 35% to 40% found in human diets, did not report any side effects or notable changes in blood glucose levels after consuming the microbeads.
When compared to Orlistat, an FDA-approved fat-blocking medication, the beads resulted in similar fat excretion rates but avoided the gastrointestinal issues commonly associated with Orlistat.
Orlistat can lead to digestive discomfort as unabsorbed fat moves through the colon. In contrast, these microbeads seemed to prevent fat and weight gain without negatively impacting blood sugar, digestion, or energy levels.
Researchers noted that semaglutide, the active ingredient in medications like Ozempic and Wegovy, managed to lower blood sugar in rats but also caused fluctuations that raised concerns around feelings of starvation and lethargy during animal trials.
“This study establishes a proof of concept for the use of PMFL microbeads in treating obesity, though it is still exploratory and not yet at the preclinical stage,” the researcher explained in their paper.
They emphasized that while the results underline fundamental mechanisms and potential advantages, further studies are essential to evaluate long-term safety, efficacy, and possibilities for clinical application.
Researchers indicated that all ingredients are food grade and FDA-approved, although the specific formulation of the microbeads is yet to receive regulatory approval.
Biotechnology firms are collaborating with researchers to boost manufacturing, with clinical trials in humans currently underway in China. Early results from these trials are anticipated within the next year.
